| abstract |
FIELD: chemistry. n SUBSTANCE: invention relates to a compound of formula (I), n n n n in which V is selected from C and N so that the aromatic ring containing V is phenyl or pyridine; R2 is absent when V is N; or, when present, R2 is selected from H, alkyl, alkoxy and halogen; R1 and R3 are independently selected from H, alkyl, alkoxy, halogen and CF 3 ; W, X, Y and Z are independently selected from C and N, so that the ring containing W, X, Y and Z is a five-membered aromatic heterocycle; where R5, R6 and R7 are independently absent or independently selected from H, alkyl, aryl and CF 3 ; P represents -C(R10)(R11)NH 2 ; A is selected from aryl and heteroaryl; alkyl is a linear saturated hydrocarbon containing up to 6 carbon atoms (C 1 -C 6 ), or a branched saturated hydrocarbon containing from 3 to 6 carbon atoms (C 3 -C 6 ); alkyl, optionally, may be substituted with -NR12R13; cycloalkyl is a monocyclic saturated hydrocarbon containing from 3 to 7 carbon atoms; alkoxy is a linear O-linked hydrocarbon containing from 1 to 6 carbon atoms (C 1 -C 6 ), or a branched O-linked hydrocarbon containing from 3 to 6 carbon atoms (C 3 -C 6 ); alkoxy, optionally, may be substituted with aryl; aryl is phenyl; aryl, optionally, may be substituted with a substituent selected from alkyl, alkoxy, halogen, CN, -morpholinyl, -piperidinyl, heteroaryl, aryl b , -O-aryl b , -CH 2 - aryl b , -(CH 2 ) 1-3 -heteroaryl, -CONR12R13, -(CH 2 ) 1-3 -NR14R15 and NR12R13; heteroaryl is a 5, 6, 9 or 10-membered mono- or bicyclic aromatic ring containing, where possible, 1 or 2 ring members, independently selected from N, S and O; heteroaryl, optionally, may be substituted with 1 or 2 substituents independently selected from alkyl, alkoxy, morpholinyl, aryl, -(CH 2 ) 1-3 -aryl, heteroaryl b and NR12R13; values of other radicals are given in the patent claim. Invention also relates to a pharmaceutical composition, to the use of a compound, to a method for treating a disease or condition in which plasma kallikrein activity is involved. n EFFECT: technical result: obtaining novel compounds capable of inhibiting plasma kallikrein. n 29 cl, 18 tbl, 7 ex |